Synthesis and characterization of a doxorubicin-Gd(III) contrast agent conjugate: A new approach toward prodrug-procontrast complexes

Inorganic Chemistry

Volumn 45, Issue 21, 2006, Pages 8489-8491

  Frullano, Luca ^a   Tejerina, Baudilio ^a   Meade, Thomas J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DOXORUBICIN; GADOLINIUM; GADOLINIUM PENTETATE; PRODRUG;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; SYNTHESIS;

CONTRAST MEDIA; DOXORUBICIN; GADOLINIUM; GADOLINIUM DTPA; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE IMAGING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR WEIGHT; PRODRUGS;

EID: 33750297579     PISSN: 00201669     EISSN: None     Source Type: Journal    
DOI: 10.1021/ic0612045     Document Type: Article

References (36)

1. Arcamone, F. Doxorubicin Anticancer Antibiotics; Academic Press: New York, 1981; Chapter 2.
2. Gewirtz, D. A. Biochem. Pharmacol. 1999, 57, 727-741.
3. Abeloff, M. D.; Armitage, J. O.; Niederhuber, J. E.; Kastan, M. B.; McKenna, W. G. Clinical Oncology, 3rd ed.; Elsevier Churchill Livingstone: Philadelphia, PA, 2004.
4. A prodrug is a pharmacological agent that is administered in an inactive form, which is converted into an active drug by metabolic processes.
5. (a) Tong, G. L.; Cory, M.; Lee, W. W.; Henry, D. W. J. Med. Chem. 1978, 21, 732-737.
6. (b) Chen, Q.; Sowa, D. A.; Cai, J.; Gabathuler, R. Synth. Commun. 2003, 33, 2377-2390.
7. (c) Willner, D.; Trail, P. A.; Hofstead, S. J.; King, H. D.; Lasch, S. J.; Braslawsky, G. R.; Greenfield, R. S.; Kaneko, T.; Firestone, R. A. Bioconjug. Chem. 1993, 4, 521-527.
8. (d) King, H. D.; Dubowchik, G. M.; Mastalerz, H.; Willner, D.; Hofstead, S. J.; Firestone, R. A.; Lasch, S. J.; Trail, P. A. J. Med. Chem. 2002, 45, 4336-4343.
9. (e) Bouhadir, K. H.; Kruger, G. M.; Yong Lee, K.; Mooney, D. J. J. Pharm. Sci. 2000, 89, 910-919.
10. (f) Mueller, B. M.; Wrasidlo, W. A.; Reisfeldt, R. A. Bioconjug. Chem. 1990, 1, 325-330.
11. (g) Kratz, F.; Warnecke, A.; Scheuermann, K.; Stockmar, C.; Schwab, J.; Lazar, P.; Druckes, P.; Esser, N.; Drevs, J.; Rognan, D.; Bissantz, C.; Hinderling, C.; Folkers, G.; Fichtner, I.; Unger, C. J. Med. Chem. 2002, 45, 5523-5533.
12. Merbach, A. E.; Toth, E. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging; John Wiley & Sons Ltd.: Chichester, U.K., 2001; p 471.
13. (a) Moats, R. A.; Fraser, S. E.; Meade, T. J. Angew. Chem., Int. Ed. Engl. 1997, 36, 726-728.
14. (b) Li, W. H.; Fraser, S. E.; Meade, T. J. J. Am. Chem. Soc. 1999, 121, 1413-1414.
15. (c) Louie, A. Y.; Huber, M. M.; Ahrens, E. T.; Rothbacher, U.; Moats, R.; Jacobs, R. E.; Fraser, S. E.; Meade, T. J. Nat. Biotechnol. 2000, 18, 321-325.
16. (d) Li, W.; Parigi, G.; Fragai, M.; Luchinat, C.; Meade, T. J. Inorg. Chem. 2002, 41, 4018-4024.
17. Duimstra, J. A.; Femia, F. J.; Meade, T. J. J. Am. Chem. Soc. 2005, 127, 12847-12855.
18. Dadabhoy, A.; Faulkner, S.; Sammes, P. G. J. Chem. Soc., Perkin Trans. 2 2002, 348-357.
19. 2O, pH 6, 60°C, 12 h, 69%. (v) 99:1 (v/v) MeOH/TFA, RT, dark, 2 days, 46%.
20. Dubost, J. P.; Leger, J. M.; Langlois, M. H.; Meyer, D.; Schaefer, M. C. R. Acad. Sci., Ser. II 1991, 312, 349-354.
21. Dale, J. Isr. J. Chem. 1980, 20 (1-2), 3-11.
22. (a) Benetollo, F.; Bombieri, G.; Aime, S.; Botta, M. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1999, C55 (3), 353-356.
23. (b) Kotek, J.; Rudovsky, J.; Hermann, P.; Lukes, I. Inorg. Chem. 2006, 45 (7), 3097-3102.
24. (c) Frullano, L.; Rohovec, J.; Peters, J. A.; Geraldes, C. F. G. C. Top. Curr. Chem. 2002, 221, 25-60.
25. Supkowski, R. M.; Horrocks, W. D., Jr. Inorg. Chim. Acta 2002, 340, 44-48.
26. Beeby, A.; Clarkson, I. M.; Dickins, R. S.; Faulkner, S.; Parker, D.; Royle, L.; de Sousa, A. S.; Williams, J. A. G.; Woods, M. J. Chem. Soc., Perkin Trans. 2 1999, 493-504.
27. Lee, J.; Zylka, M. J.; Anderson, D. J.; Burdette, J. E.; Woodruff, T. K.; Meade, T. J. J. Am. Chem. Soc. 2005, 127, 13164-13166.
28. Powell, D. H.; Ni Dhubhghaill, O. M.; Pubanz, D.; Helm, L.; Lebedev, Y. S.; Schlaepfer, W.; Merbach, A. E. J. Am. Chem. Soc. 1996, 118, 9333-9346.
29. Ruloff, R.; Muller, R. N.; Pubanz, D.; Merbach, A. E. Inorg. Chim. Acta 1998, 275-276, 15-23.
30. Cohen, S. M.; Xu, J.; Radkov, E.; Raymond, K. N.; Botta, M.; Barge, A.; Aime, S. Inorg. Chem. 2000, 39, 5747-5756.
31. Hajela, S.; Botta, M.; Giraudo, S.; Xu, J.; Raymond, K. N.; Aime, S. J. Am. Chem. Soc. 2000, 122, 11228-11229.
32. Costa, J.; Toth, E.; Helm, L.; Merbach, A. E. Inorg. Chem. 2005, 44, 4747-4755.
33. (a) Gupta, P. K.; Lam, F. C.; Hung, C. T. Drug Dev. Ind. Pharm. 1988, 14, 1657-1671.
34. (b) Beijnen, J. H.; Van der Houwen, O. A. G. J.; Underberg, W. J. M. Int. J. Pharm. 1986, 32, 123-131.
35. (c) Wood, M. J.; Irwin, W. J.; Scott, D. K. J. Clin. Pharm. Ther. 1990, 15, 279-289.
36. (e) Janssen, M. J. H.; Crommelin, D. J. A.; Storm, G.; Hulshoff, A. Int. J. Pharm. 1985, 23, 1-11.